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Abstract 
Background: Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) commonly known as hyper-
glycemic emergencies are the two most common life-threatening acute metabolic complications of diabetes. The 
objective of this study is to assess predictors and treatment outcome of hyperglycemic emergencies (HEs) among 
diabetic patients admitted to Jimma University Specialized Hospital (JUSH).
Methods: It is a three year retrospective review of medical records of patients admitted with HEs at JUSH. Patient 
demographics, admission clinical characteristics, precipitants, insulin used and treatment outcomes were extracted. 
Statistical analysis was done using student’s t test, Chi square test, and binary logistic regression with level of α set at 
0.05. Statistical significance was considered for variables with p < 0.05.
Results: Complete data was available for 163 out of 421 patients admitted with HEs. The majority (62.6 %) were 
males. Mean age of patients was 36.6 ± 15.9 years. About 64 % of patients had type 1 diabetes. About 93 % of the 
participants developed DKA. The most common precipitants of HEs were infections 95 (59 %), non-compliance to 
medications 52 (32.3 %), and newly diagnosed diabetes 38 (23.6 %). Recurrent hyperglycemia, hypoglycemia and 
ketonuria occurred in 88 (54 %), 34 (20.9 %) and 31 (20.5 %) patients respectively. Mean amount of insulin used 
and duration of treatment till resolution of DKA were 136.85 ± 152.41 units and 64.38 ± 76.34 h respectively. The 
median length of hospital stay was 6 days. Mortality from HEs was 16 (9.8 %). Admission serum creatinine >1.2 mg/dL 
(P = 0.018), co-morbidity (P < 0.001) and sepsis (P = 0.014) were independent predictors of HEs mortality.
Conclusions: Infections, non-compliance and new onset diabetes were the most common precipitants of HEs. 
Length of hospital stay and mortality were high. High use of insulin, recurrent hyperglycemia, hypoglycemia, and 
ketonuria were common during HEs management. Elevated serum creatinine, sepsis and co-morbidity are independ-
ent predictors of HEs mortality.
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Background
Diabetes mellitus (DM) is frequently associated 
with acute non-metabolic and metabolic complica-
tions. Diabetic ketoacidosis (DKA) and hyperosmolar 
hyperglycemic state (HHS), commonly known as hyper-
glycemic emergencies (HEs), are the two most common 
life-threatening acute metabolic complications of diabe-
tes [1]. DKA occurs in type 1 and most often HHS occurs 
in type 2 diabetes; however, each type of diabetes may 
be associated with DKA or HHS [2]. These complica-
tions are usually associated with disability, reduced life 
expectancy and enormous health costs for virtually every 
society [3] with mortality rates ranging from 2 to 5 % for 
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DKA and up to 15 % for HHS [4, 5]. In the United States 
of America, 43 % of the total medical costs for diabetes 
is spent on hospital inpatient care [6]. The costs of DKA 
treatment are significant, with estimated mean expenses 
for a single hospitalization ranging from $7470 to $20,864 
[7].
In Ethiopia the prevalence of diabetes is increasing for 
the last two to three decades becoming a major economic 
problem in drug use and bed occupancy [8]. The control 
of diabetes and prevention of ketoacidosis in Ethiopian 
patients is hampered by socioeconomic factors, particu-
larly the cost and unreliability of insulin supplies [9]. Dia-
betes is a frequent cause of morbidity and mortality in 
Ethiopia because of scarce inpatient facilities and limited 
resources [10].
More than one-third, but less than half, of diabetic 
patients in Ethiopia receives standard diabetes care [11]. 
Access for blood glucose monitoring and diabetic edu-
cation in the country is low resulting in poor control of 
hyperglycemia often related to poverty and interruption 
of therapy for many social and economic reasons. For 
example, 95  % of DM patients don’t perform self-blood 
glucose monitoring at home, 33 % don’t take their treat-
ments regularly, 75 % require admissions directly or indi-
rectly due to uncontrolled diabetes [12, 13].
The cost of inpatient diabetes management in the 
country is enormous and significantly higher than the 
cost of other inpatient managements [8, 10]. DKA is a 
common cause for diabetic admission in about 71.1  % 
of diabetic admissions with a mortality of 5.8  % [14]. 
Among DM patients on follow up at JUSH, only 18.1 % 
of patients were able to control their fasting blood sugar 
below 7 mmol/l [15] and DKA was the commonest acute 
complication and cause of hospital admission [16, 17]. 
Despite all the challenges and costs incurred by diabetes 
and its complications, studies are limited on the overall 
treatment complications, precipitants, length of hospital 
stay and mortality of acute metabolic diabetes complica-
tions (HEs) in the country. Hence forth, this study aimed 
to assess such problems faced by diabetic patients admit-
ted with HEs and predictors of HEs mortality.
Research methods and participants
We conducted a retrospective review of the medical 
records of adolescent and adult diabetic patients with 
HEs admitted to JUSH from January 01/2011 to Decem-
ber 31/2013. JUSH is a public hospital with 523 beds 
serving for approximately 20,000 admissions and 140, 
000 outpatient visits a year with a catchment population 
of about 15 million people. Diabetes clinic at the hospi-
tal provides twice weekly outpatients services to over 100 
diabetic patients a week. Antidiabetic medication(s) dose 
adjustment and regimen change is made based on patient 
fasting blood glucose readings on subsequent visits as the 
hospital does not use glycated hemoglobin (HbA1C) test 
for regular glucose monitoring of diabetic patients.
Ethical clearance was obtained from Jimma University 
Collage of Public Health and Medical Sciences Ethical 
Review Committee to conduct the study. Official let-
ter was obtained from JUSH Clinical Director to access 
the participants’ medical records for data abstraction. 
As the study was done on patient medical records ret-
rospectively, no written informed consent and/or ascent 
for participation in the study were required from partici-
pants. However, patient records were handled properly 
during the data collection process and ethics of research 
was maintained. Medical record of patients with HEs 
admitted to the hospital were traced retrospectively in 
a reverse chronological order from patient logbook and 
drawn from card room. Selection of medical records for 
sampling was based on the physician’s confirmed diag-
nosis on patient logbooks. Participants included in the 
study were all Diabetic patients with HEs admitted to 
JUSH with age ≥15 years old whose medical records con-
tained complete pertinent data. Pregnant mothers admit-
ted with HEs were excluded from the study. The data was 
collected by the Medical Interns of Jimma University stu-
dents practicing at the hospital.
Data extracted included sociodemographic characteris-
tics, type of diabetes, duration of diabetes and duration 
of treatment, admission blood pressure, laboratory inves-
tigations (admission blood glucose, serum electrolytes, 
Blood Urea Nitrogen, and Serum Creatinine at presenta-
tion), antidiabetic and concomitant medications, precipi-
tants, co-morbidities, amount of insulin used, duration 
of therapy till HEs resolution and treatment outcomes. 
Patients with incomplete data such as demographics, 
admission laboratory tests, treatment interventions and 
outcomes were excluded. Over a three year period, a 
total of 421 patients were admitted with HEs of which 
only 163 patients’ medical records contained complete 
information and studied. The main outcome of the study 
was in hospital mortality due to HEs and secondary out-
comes were episodes of hypoglycemia during treatment, 
hyperglycemia and ketonuria after resolution of HEs and 
Length of hospital stay.
Statistical analysis
Data was analyzed using SPSS Version 16.0 (Chicago, 
SPSS Inc.). Student’s t test was used for comparison 
of means of continuous variables. To see the associa-
tion between categorical variables, Chi square tests or 
Fisher exact tests were used. To examine independent 
predictors of mortality, variables with p-values <0.25 
on a bivariate binary logistic regression model were 
entered into a multivariate logistic regression model and 
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variables with p-value <0.05 were considered statistically 
significant.
Operational definitions
DKA was defined as admission blood glucose >250 mg/l 
and urine dipstick ketone level ≥ +2 and HHS was 
defined as blood glucose >600 mg/dL, alteration in men-
tal status and mild or absent ketonuria. Hyperglycemia 
was defined as random plasma glucose >200  mg/dL 
and Hypoglycemia was defined as a blood glucose level 
<70 mg/dL. Sepsis was defined as the presence of known 
or suspected infection plus two or more of the follow-
ing: Temperature >38 or <36 °C, HR >90, RR >24, WBC 
>12,000/mm3 or <4000/mm3.
Results
Baseline characteristics of patients with hyperglycemic 
emergencies
A total of 421 diabetic patients were admitted and treated 
for DKA and HHS at JUSH over a three year period. Of 
these patients, only 163 of them had complete data and 
were included in the study. Hundred-two (62.60  %) of 
them were males. The mean age of the participants was 
36.57  ±  15.91 (range 15–84  years). About 48  % of the 
participants were below 35 years old. More than half of 
the patients (56.4 %) were from urban and the remaining 
74 (43.6  %) were rural residents. Family history of dia-
betes was reported in only 2 of the patients. The major-
ity, 104 (63.8 %), of the participants had type 1 diabetes. 
All type 1 and 47 (79.7  %) of type 2 diabetic patients 
developed DKA while HHS was noted in type 2 diabet-
ics (P < 0.001). Overall, there were 151 (92.6 %) cases of 
DKA and 12 (7.4 %) cases of HHS. All HHS cases were 
seen in patients older than 34 years.
Seventy four (45.4 %) of the patients were newly diag-
nosed with diabetes at admission and the remaining 89 
(54.6  %) were known diabetic patients on follow up at 
JUSH diabetic clinic. Eighty five (95.5  %) of the known 
diabetic patients developed DKA. Eight (66.7 %) out of 12 
who developed HHS were new DM patients. The major-
ity, 94 (57.7 %), of the participants had diabetes for less 
than a year while only 6 (3.7 %) patients had diabetes for 
more than 10 years. Ninety five (58.3 %) of the study sub-
jects were on antidiabetic medications for <1  year. No 
HHS patient had either diabetes or was on antidiabetic 
medications for more than 5 years.
A total of 87 (53.4  %) patients were on antidia-
betic medications prior to admission out of which 58 
(66.7 %) were on insulin and 26 (29.9 %) on oral glucose 
lowering agents (OGLAs). The remaining 3 patients 
were on insulin +  OGLAs. Out of the 29 patients who 
were on OGLAs, 8 (27.6  %) were on Glibenclamide, 
9 (31  %) were on Metformin and 12 (41.4  %) were on 
Glibenclamide  +  Metformin. All patients who were on 
insulin developed DKA (P = 0.005). Eighty three (95.4 %) 
of the patients who were on antidiabetic medications 
developed DKA. Thirteen (8.0 %) out of 163 patients had 
been taking concomitant medications prior to admission. 
There were 36 (22.1  %) patients with co-morbidities of 
which 15 (41.7 %) had hypertension, 7 (19.5) had cardio-
vascular disease, 6 (16.7 %) had stroke and the remaining 
had viral hepatitis, chronic kidney disease and malignan-
cies. Eleven patients (6.7) had history of hospital admis-
sion due to HEs within the past 12 months.
Hypotension (BP <90/60  mmHg) on admission 
was noted in 8 (4.9  %) of the patients. Hypokalemia 
(serum K+ <3.5  mEq/L) and hyponatremia (Serum Na+ 
<135 mEq/L) at admission were observed in 37 (22.7 %) 
and 48 (29.4  %) of the patients respectively. There were 
34 (20.9 %) patients with elevated admission serum cre-
atinine (>1.2  mg/dL). The Mean admission blood glu-
cose was 464.93  ±  99.81  mg/dL. Mean durations of 
diabetes and antidiabetic treatment were 2.42  ±  4.02 
and 2.36 ±  3.96 years respectively. Most of the patients 
131 (80.4  %) had admission GCS =  15 and the remain-
ing 32 (19.6 %) had admission GCS <15. Admission urine 
ketone for DKA patients ranged from +2 to +4 with pre-
ponderance of +2 level in 81 (49.7 %) of the patients.
Admission characteristics of DKA and HHS patients 
are compared in Table  1. Patients with HHS were sig-
nificantly older than those with DKA (56.25  ±  8.68 vs. 
35.00 ± 15.31 years, P < 0.001).
Precipitants of hyperglycemic emergencies
Precipitating factors of HEs were determined for 161 
(98.8 %) of the patients. The most common precipitants 
of HEs were infections 95 (59 %), non-compliance to anti-
diabetic medications 52 (32.3  %) and newly diagnosed 
diabetes 38 (23.6 %). The major cause of non-compliance 
was medication discontinuation which was reported 
in 45 (86.5 %) of the patients. Urinary tract infection 61 
(64.2  %) was the most common infection that precipi-
tated HEs (Table 2).
Treatment interventions and outcomes of patients 
with HEs
Mean amount of insulin used (units) till resolution of 
DKA was 136.85 ±  152.41 whereas 71.83 ±  33.29 units 
of insulin were used till HHS resolution. The dura-
tions of treatment till resolution of DKA and HHS were 
64.38  ±  76.34 and 29.00  ±  20.58  h respectively. The 
majority, 88 (54 %), of patients experienced one or more 
episodes of hyperglycemia after resolution of HEs. Epi-
sodes of hypoglycemia were noted in 34 (20.9 %) of the 
patients (Table 3). The overall in hospital mortality due to 
HEs among the study subjects was 16 (9.8 %).
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The median length of hospital stay was 6 days; 7 days 
for DKA patients and 5  days for HHS ones. The large 
majority, 87 (53.4  %), of patients had length of hos-
pital stay 1–7  days. Ten (6.1  %) patients stayed at the 
hospital for more than 28  days. Most of the deaths, 14 
(87 %), occurred within the first seven days of admission 
(p = 0.011).
Mortality rate in males was higher than in females (11.8 
vs. 6.6  %), however, it was not statistically significant 
(P = 0.286,). The highest mortality rate was observed in 
age groups ≥65 years, 3 (37.5 %) whereas the lowest mor-
tality rate occurred in 15–24 age groups, 1 (2.5  %). The 
number of deaths in type 1 DM and type 2 DM patients 
was equal (8 in each). Mortality among known DM 
patients, 13 (14.6  %), was higher than among new ones 
3 (4.1  %); P  =  0.035. The highest mortality, 8 (30.8  %), 
was recorded in patients with 6–10 years duration of dia-
betes and antidiabetic treatment (P  <  0.001). No death 
was recorded in patients with durations of diabetes and 
antidiabetic treatment above 10  years. Six (46.2  %) out 
of 13 patients taking concomitant medications were died 
(P < 0.001) and 12 (33.3 %) patients died out of 36 who 
had co-morbidity (P < 0.001).
On a multivariate model (Table  4), independent pre-
dictors of mortality were elevated admission serum cre-
atinine >1.2  mg/dL (AOR  =  5.86, 95  % CI: 1.36–25.28, 
P  =  0.018), sepsis (AOR  =  9.83, 95  % CI: 1.59–60.79, 
P  =  0.014) and co-morbidity (AOR  =  15.26, 95  % 
CI = 3.67–63.41, P < 0.001).
Discussion
Our study showed that DKA was the most common diag-
nosis among diabetic patients with HEs and infection 
was the leading precipitating factor of HEs admission. 
Metabolic complications during treatment were com-
mon. Lengths of hospital stay and in hospital mortality 
of HEs were high. Elevated admission serum creatinine, 
sepsis and co-morbidity were found to be independent 
predictors of HEs mortality.
We found that DKA and HHS occurred in 92.6 and 
7.36  % diabetic patients with HEs respectively. In this 
study the proportion of DKA patients was higher than 
the findings from other studies, while that of HHS was 
lower than the same findings [18–20].
The reasons for the higher proportion of DKA in our 
finding may be due to the combined effect of: (1) DKA 
was common in type 1 diabetes where the majority of 
patients in our study are type 1 diabetics, (2) there are 
reports [21] that DKA is common in known diabetics and 
the majority of our patients were known diabetics and on 
antidiabetic treatment who were non-compliant to their 
Table 1 Admission characteristics of  diabetic patients 
by type of HE at JUSH
SBP systolic blood pressure, DBP diastolic blood pressure, BUN blood urea 
nitrogen, GCS Glasgow Coma Scale
* Statistically significant
Parameter DKA (Mean ± SD) HHS (Mean ± SD) P-value
Age (years) 35.00 ± 15.31 56.25 ± 8.68 <0.001*
Blood glucose (mg/
dL)
454.20 ± 95.83 >600.00 <0.001*
SBP (mmHg) 113.61 ± 23.64 95.83 ± 33.97 0.017*
DBP (mmHg) 74.44 ± 13.68 62.50 ± 22.21 0.006*
Serum potassium 
(mEq/L)
3.78 ± 0.47 3.70 ± 0.57 0.591
Serum sodium 
(mEq/L)
137.71 ± 4.52 135.46 ± 7.17 0.116
Serum chloride 
(mEq/L)
109.67 ± 7.42 107.79 ± 6.49 0.395
Serum creatinine 
(mg/dL)
1.18 ± 0.99 1.63 ± 0.97 0.135
GCS 14.52 ± 1.61 14.00 ± 1.21 0.273
Table 2 Precipitants of  HEs of  diabetic patients admitted 
to JUSH
UTI urinary tract infection, TB tuberculosis, DFU diabetic foot ulcer
NB total percentage is >100 % as there were multiple response questions




Newly diagnosed DM 38 (23.6)
Trauma (injury) 1 (0.6)





 Medication(s) discontinuation 45 (86.5)
 Missed dose of medication 7 (13.5)





Pulmonary TB 4 (4.2)
Oral infections 3 (3.2)
Insulin injection site infection 3 (3.2)
DFU 3 (3.2)
Osteomyelitis 2 (2.1)
Gastrointestinal infection 2 (2.1)
Bacterial meningitis 2 (2.1)
Others 13 (13.7)
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medications (52 out of 87 patients that were on treatment 
were non-compliant), (3) most of the patients were in an 
actively growing and working age group (15–44  years) 
whose insulin demand may fluctuate based on their daily 
activities that need dose adjustment based on demand 
and (4) high infection rate recorded as the most common 
precipitant which may increase insulin demand leading 
to ketoacidosis.
Admissions for HHS, in contrast to DKA, were more 
common in patients with a new diagnosis of diabetes 
(66.7 %). This is in line with the finding from South Africa 
[22], but against the study from Taiwan [23] where HHS 
was more common in known DM patients than newly 
diagnosed ones (72.3 vs. 27.7 %).
The higher incidence of HHS in new DM patients in 
our finding and the similarity to the finding from South 
Africa may be related to relatively older age of patients 
with HHS (91.67  % of HHS patients were ≥45  years in 
our study whereas all patients were >40 years old in the 
South African study) where hyperosmolarity is usually 
related to an age-related increase in the renal threshold 
for glucose and reduced sensitivity of the thirst centre. It 
is also possible that as HHS admissions were mainly of 
newly diagnosed diabetic subjects who were not aware of 
their diabetes status, they may have presented relatively 
late due to delayed recognition of hyperglycemic symp-
toms or not taken adequate fluids to replenish ongoing 
fluid losses (which an informed known diabetic patient 
could do so). It also suggests that many adult patients 
remain undiagnosed of diabetes and present for medi-
cal attention after developing diabetic complications and 
worsening of the conditions.
The most common precipitants of HEs in our study 
were infections 59  %, non-compliance to antidiabetic 
medications 32.3  % and newly diagnosed DM 23.6  %. 
These values are higher than the findings from Paki-
stan and South Africa [24, 25]. However, a higher rate of 
infection than our finding was reported from Thailand 
[26]; 73.5 vs. 59 %.
Poor infection prevention strategies by the patients 
either due to poor patient awareness or the underly-
ing poverty might have contributed to the higher rate of 
infection in our study. It is also possible that about 45 % 
of the patients is newly diagnosed at admission whose 
awareness of self care and infection prevention may be 
low. There is a report [27] that, in Sub Saharan Africa, 
healthcare systems are scarce due to widespread poverty 
of individuals and nations alike calling for the need for 
empowerment of individuals and populations through 
education, nutrition and poverty eradication to improve 
self-care in health and living with diabetes.
The rate of non-compliance in our finding was lower 
than the findings from America, Thailand, Nigeria and 
Kenya that range from 34 to 69  % [18, 26, 28–30]. This 
may be attributed to the high number of patients with no 
prior treatment (46.6  %) which might have contributed 
to the decrease in total percentage of non-compliance 
rate. Otherwise, this non-compliance rate is not accept-
able and hence patient education, improvement in acces-
sibility of nearby health facilities that provide medical 
care for diabetics and economic empowerment of DM 
Table 3 Frequency of metabolic complications and prognosis of diabetic patients with HEs admitted to JUSH
Parameter DKA HHS Total P-value
Frequency (%) Frequency (%) Frequency (%)
Episodes of hyperglycemia 82 (93.2) 6 (6.8) 88 (54.0) 1.00
Episodes of hypoglycemia 33 (97.1) 1 (2.9) 34 (20.9) 0.463
Episodes of ketonuria (DKA) 31 (100.0) – 31 (20.5) 0.125
Died 15 (9.9) 1 (8.3) 16 (9.8) 1.00
Improved and discharged 135 (92.5) 11 (7.5) 146 (89.6) 1.00
Left against medical advice 1 (100.0) 0 1 (0.6) 0.074
Table 4 Independent predictors of  HEs related mortality 
of diabetic patients admitted to JUSH
a AOR adjusted odds ratio
Variable category Died P-value AORa (95 % CI)
Yes (n) No (n)
History of DM
 New DM 3 71 1
 Known DM 13 76 0.057 4.88 (0.95–24.97)
Serum creatinine (mg/dL)
 <0.5 0 2 0.999 0 (0)
 0.5–1.2 8 119 1
 >1.2 8 26 0.018 5.86 (1.36–25.28)
Co-morbidity
 No 4 123 1
 Yes 12 24 <0.001 15.26 (3.67–63.41)
Sepsis
 No 10 143 1
 Yes 6 4 0.014 9.83 (1.59–60.79)
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patients may be warranted. It has been reported [27, 31] 
that stopping insulin for economic reasons, unavailability 
and unaffordability of insulin, missed clinics, perceived 
ill-health and alternative therapies like herbs, prayers and 
rituals are common problems that contributed to non-
compliance to antidiabetic medications in the Tropical 
and Sub-Saharan African diabetic patients.
We found that the mean amount of insulin used till 
resolution of DKA and HHS was 136.85  ±  152.41 and 
71.83  ±  33.29 units respectively. The mean amount of 
insulin used till resolution of DKA in our study was far 
higher than the mean amounts of insulin used in the 
studies from America [32–34]. The mean duration of 
treatment till resolution of DKA in our study was more 
than five times (64.38  ±  76.34  h) the time needed in 
other studies [32–34]. The higher amount of insulin use 
and longer duration of treatment until DKA resolution as 
compared to other studies can be explained by; firstly, the 
difference in the management protocol of DKA between 
ours and other studies. Other studies used continuous 
intravenous infusion of regular insulin at high care cent-
ers (intensive care units) to manage DKA while in our 
study they were treated at general medical wards with 
sliding scale insulin. Secondly, the pharmacokinetic dif-
ference between intramuscular (IM) and/or subcutane-
ous (SC) and continues intravenous infusion of regular 
insulin. Thirdly, in our study DKA is said to be resolved 
based on blood glucose, urine dipstick ketone clear-
ance and clinical parameters while in other studies it is 
based on blood glucose, PH and serum bicarbonate levels 
which are more objective than ours. In addition, the com-
mitment of multidisciplinary team to monitor patients 
closely and administer hourly IM (SC) insulin injection, 
severity of DKA at presentation, and the presence of co-
morbidities might have contributed for this difference. 
The use of SC insulin injections on an hourly schedule is 
reported to be difficult to follow in many medical cent-
ers because of the intensity of treatment and shortage of 
nursing staff in general wards [33, 34].
Fisher et al. [35] reported that, in DKA patients treated 
either with IM or SC injections or with continuous IV 
infusion of regular insulin, 30–40  % of patients in the 
IM and SC groups did not lower their plasma glucose 
by 10 % in the first hour after insulin injection and that 
the concentration of ketone bodies was lowered at a sig-
nificantly faster rate in the IV group than with IM or SC 
insulin. The delay in onset of action of regular insulin was 
supported by the report of Menzel and Jutzi [36], who 
treated patients with frequent small SC injections, but 
only 4 of 24 patients showed a fall in blood glucose con-
centration in the first 3 h of therapy. It was also reported 
that the mean hourly rate of fall of plasma glucose level 
was significantly higher in patients treated with intra-
venous insulin therapy group than patients treated with 
intramuscular insulin therapy [37]. These differences in 
response can be explained by delays in reaching a ther-
apeutic plasma insulin concentration to produce the 
desired response.
The median length of hospital stay was 6  days range 
from 1 to 59  days. This finding was far lower than the 
finding from the study by Ezeani et  al. [20] and higher 
than other studies [3, 38]. The reason for the longer dura-
tion of hospital stay in our finding is unclear and prob-
ably further research may be needed. The reason for a 
shorter duration of hospital stay in our finding may be 
related to initial patient presentation. For example, DFU 
was common in the study we compared whereas only 3 
patients had DFU in our study. It was reported that [20, 
38] DFU is usually associated with a much longer dura-
tion of hospital stay.
In our finding episodes of hyperglycemia (54.0 %) was 
lower than the report from Thailand [26] while hypogly-
cemic episodes (20.9 %) in our study were higher than the 
same study in Thailand (15.7  %). Though we are uncer-
tain to explain the noted difference in hyperglycemic epi-
sodes between our patients and the Thailand’s, it might 
possibly be related to the difference in patient character-
istics at presentation as infection and admission blood 
glucose were higher than ours. This may be substantiated 
by the reports from Queale et  al. [39] where severity of 
illness, severe diabetic complications, high admission 
glucose level and admission for infectious disease were 
found to be independent predictors of hyperglycemic 
episodes. The higher hypoglycemic episodes documented 
in our finding may be related to infrequent patient blood 
glucose and urine dipstick ketone monitoring to adjust 
insulin doses based on patient need that may lead to 
inadvertent use of insulin resulting in hypoglycemia.
We noted that episodes of hypoglycemia among DKA 
patients were 21.9  %. This figure is higher than other 
studies that reported 5 and 6.7 % [33, 34] respectively and 
lower than the reports from Guillermo et al. [32]. While 
the higher hypoglycemic events in our study might be 
due to the differences in DKA management protocol and 
set up and infrequent laboratory monitoring in our set 
up, the reasons for lower hypoglycemic events may need 
further investigation.
The overall mortality of HEs in this study was 9.8  %. 
This is higher than other studies [19, 20, 26, 38, 40] that 
reported mortality rates ranging from 3.57 to 8.4 % and 
lower than the findings from Nigeria [18] and Kenya [30]. 
The higher mortality rate in our finding may be explained 
by the difference in inpatient management protocol of 
HEs, presenting precipitants, age, co-morbidities, and 
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absence of adequate laboratory investigations at pres-
entation, inadequate laboratory monitoring during 
treatment to monitor patient response. The lower mor-
tality rate in our finding as compared to the Nigeria and 
Kenya studies possibly lays on the difference in patient 
characteristics.
The majority of deaths (81.2 %) occurred in known DM 
patients (P  =  0.047) and all deaths were documented 
in patients with <11  years of diabetes duration prior to 
presentation. This is comparable with the findings by 
Ogbera et  al. [18] and Ezeani et  al. [20] who reported 
that (78.2 %) and all the mortalities respectively were in 
subjects who had diabetes duration of less than 10 years 
prior to presentation. This may be due to ignorance of 
diabetes complications and the need for early presenta-
tion to the hospital when complications arise.
Age above 65  years old, previously known DM, 
DM duration 6–10  years, antidiabetic treatment for 
6–10  years, SBP >159  mmHg, DBP >99  mmHg, SeCr 
>1.2  mg/dL, concomitant medications, co-morbidity, 
and sepsis are found to have a significant association 
with HEs related mortality on a bivariate logistic regres-
sion model; however, only elevated admission serum 
creatinine (>1.2  mg/dL), co-morbidity, and sepsis are 
independent predictors of HEs related mortality on a 
multivariate logistic regression model.
Conclusions and recommendations
In conclusion, our study revealed that DKA is the index 
presentation of HEs. Infections, non-compliance to 
antidiabetic medications and new onset diabetes were 
the most common precipitants of HEs. The amount of 
insulin required and the time needed till resolutions of 
DKA were found to be high. Recurrent hyperglycemia, 
hypoglycemia and ketonuria were common problems 
seen during the management of HEs. Length of hospi-
tal stays and mortality rate from HEs were abnormally 
high. Elevated admission serum creatinine, co-morbid-
ity and sepsis are independent predictors of HEs mor-
tality. Therefore, promoting self-monitoring of blood 
glucose, patient education on diabetes self-care prac-
tices and infection prevention strategies, developing 
evidence based HEs treatment protocol, organizing HEs 
managing multidisciplinary team and availing biochem-
ical tests at affordable costs may help prevent hyper-
glycemic related admissions and unwanted treatment 
outcomes. Treating physicians should also detect and 
manage precipitants of HEs and co-morbidities early 
at initial patient presentation. At last, we recommend 
large scale multicenter prospective studies to assess the 
limitations in HEs management in Ethiopians and to 
devise strategies for cost-effective and evidence-based 
treatment.
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